Near-infrared-based hematocrit prediction of dried blood spots: An in-depth evaluation

Lisa Delahaye a,1, Liesl Heughebaert a,1, Christoph Lühr b, Stijn Lambrecht c, Christophe P. Stove a,∗

a Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent, Belgium
b BÜCHI Labortechnik GmbH, Essen, Germany
c Laboratory of Clinical Chemistry and Hematology, Ghent University Hospital, Ghent, Belgium

ARTICLE INFO

Keywords:
Dried blood spots
Hematocrit prediction
Near-infrared

ABSTRACT

Background: Dried blood spot (DBS) microsampling has gained interest in different clinical fields, owing to its many advantages compared to conventional blood sampling. However, whilst being applied for decades for screening purposes, some challenges, such as the hematocrit (Hct) effect, hinder further widespread use of DBS for quantitative purposes in clinical practice. Amongst the approaches that were developed to cope with this issue, is the Hct prediction of DBS using near-infrared (NIR) spectroscopy.

Methods: Using left-over EDTA-anticoagulated patient samples, the accuracy and precision, stability, and robustness were assessed. Furthermore, applicability of the method on capillary DBS was evaluated via finger prick samples.

Results: A maximal bias, respectively CV, of 0.012 L/L and 4.5% were obtained. The method was robust towards several aspects, including storage (except for storage at 60 °C), measurement location, type of filter paper and spotted volume. Furthermore, the potential to predict the Hct of capillary DBS was demonstrated.

Conclusion: A commercially available NIR set-up was extensively and successfully validated, allowing non-contact Hct prediction of DBS with excellent accuracy and precision. This allows to correct for the Hct-based bias observed in partial-punch DBS analysis and the set-up of blood-plasma conversion factors, increasing the application potential of patient-centric sampling.

1. Introduction

In different clinical fields, and in particular in therapeutic drug monitoring (TDM), the interest in dried blood sampling keeps growing. Capillary dried blood sampling, where samples are obtained from a finger or heel prick, has many advantages over traditional blood sampling. The best-known dried blood sampling technique is the generation of dried blood spots (DBS) on filter paper. Since it was first introduced by Guthrie and Susi for newborn screening [1], DBS have been used for a wealth of applications, both in pediatrics and in many other fields, including toxicology [2].

Evidently, DBS sampling has some specific advantages and challenges, with as key advantage primarily the patient centricity, with a minimally invasive procedure (finger prick) allowing the collection of a minimal volume of a representative matrix (blood), in a non-supervised setting (e.g. at home). This makes the approach particularly attractive for children, where both the sampling procedure (causing anxiety) and the sampling volume may be limiting factors. Amongst the main challenges associated with DBS sampling for quantitative purposes is the so-called hematocrit (Hct) effect [3], which has an analytical and a physiological aspect [4]. For the former, the most important consequence is the differential area over which a drop of blood of the same volume spreads depending on the Hct, thereby possibly affecting analytical results when sub-punches of the DBS are...
used. The physiological aspect on the other hand, includes the conversion of measurement results in blood to a concentration in plasma or serum, which are often the standard matrices in which reference intervals are determined [3]. Whilst in a general healthy population the overall impact of the Hct will remain limited, much larger variations may be seen in patients, with the largest variations seen in children [3,5,6].

In recognition of this problem, many alternative sampling devices have been proposed as an alternative to conventional DBS sampling, aiming at overcoming one or more facets of the Hct effect [7]. Nonetheless, conventional DBS cards remain valuable to collect dried blood microsamples, not in the least because DBS sampling is well known in the newborn and pediatrics field, the analysis can easily be automated and the cost is low. Therefore, in conjunction with the development of alternative sampling devices, also methodologies to predict the Hct from non-volumetrically collected DBS have been set up. This predicted Hct allows (i) to compensate for the Hct effect via dedicated algorithms, (ii) to verify whether the Hct of a DBS sample is within a validated range, or (iii) to calculate plasma or serum concentrations based on DBS results [7–15].

Two non-contact approaches, allowing to predict the Hct of DBS via mere scanning of the DBS card, have been proposed: ultraviolet-visible spectroscopy (UV/Vis) and near-infrared spectroscopy (NIR) [8,10,13,14]. While proof-of-concepts of NIR-based Hct prediction have already been reported, these used in-house generated configurations, compromising widespread use and implementation. Here, we used an existing commercially available NIR set-up to perform an extensive validation of the accuracy and precision, as well as an in-depth evaluation of the robustness, of NIR-based Hct prediction. We also evaluated its applicability to assess the Hct of capillary DBS obtained from healthy volunteers.

2. Materials and methods

2.1. Instrumentation

NIR measurements were performed on a NIRFlex N-500 Fourier Transformation spectrometer equipped with a fiber optics solids cell N500-007 (Büchi Labortechnik, Flawil, Switzerland). The instrument was controlled by the NIRWare 1.6 Operator software (Büchi Labortechnik), in which the calibration model was incorporated to predict the Hct values, expressed as L/L. Spectra were recorded between 10,000 and 4500 cm⁻¹ at a resolution of 4 cm⁻¹ and scanning each sample 12 times.

The Hct (L/L) determined with a Sysmex XN-5000 hematology analyzer (Sysmex, Kobe, Japan) was used as the reference value. The Hct of liquid capillary blood samples was determined via centrifugation in a Hct-centrifuge (5 min, 12,000 rpm), and then measured using a micro-hematocrit reader (Hawksley, Lancing, UK). Hemolytic, icteric and lipemic (HIL) indices and protein concentrations were measured with an Abbot Architect c16000 (Abbott, Illinois, US). HbA1c concentrations were measured with a Tosoh G8 HPLC analyzer (Tosoh, Pennsylvania, US).

2.2. Sample collection and preparation

This study was approved by the ethics committee from Ghent University Hospital (EC2018/0519). Left-over venous EDTA-anticoagulated patient samples from Ghent University Hospital were used to generate DBS by pipetting 25 µL of whole blood onto Whatman 903 filter paper (GE Healthcare, Dassel, Germany), unless otherwise specified. After drying at room temperature (RT) for 2 h, the DBS were further dried in resealable bags with desiccant for a minimum of 24 h before analysis. Patient samples were used for the evaluation and update of the calibration model, validation of the method, evaluation of the robustness, and method comparison.

For the application of the method on capillary DBS, blood was collected from 12 healthy volunteers via finger prick. Each volunteer provided 3 capillary DBS and 3 corresponding liquid capillary samples, the latter being collected via heparinized microcapillaries.

2.3. Calibration model

Initially, an existing calibration model for Hct prediction was used, based on a partial least squares (PLS) algorithm set-up with the NIRCal 5.6 software [13], with a calibration range from 0.150 to 0.600 L/L. A more detailed description of the PLS algorithm used can be found in the Supplementary Material Section 1.1. Prior to validation of the method, this ‘historic’ calibration model was evaluated and updated, using left-over patient samples. A detailed description of these evaluations can be found in the Supplementary Material Section 1.2.

2.4. Validation

The method validation was based on internationally accepted guidelines for bioanalytical method validation, as well as on the IATDMCT guideline for DBS-based method validation [16–18]. The method validation was performed using 49 left-over patient samples and encompassed accuracy, precision, sample storage and incurred sample reanalysis. The set-up of the method validation experiments is described in detail in the Supplementary Material Section 1.3.

2.5. Robustness

After a short (approximately 2’) introduction on the use of the NIR instrument, two additional operators, unacquainted with the system, independently measured the DBS from the validation set (n = 49; singlicate analysis). The results were compared to the Hct predictions of the regular operator on the same day.

To evaluate other robustness aspects of the methodology, 12 DBS were generated from again an independent set of left-over patient samples (Hct range 0.199–0.513 L/L). DBS with different volumes (10, 17, 25, 50, and 100 µL) were generated from these samples, to evaluate the influence of the spotted volume on the Hct prediction, taking the 25 µL DBS as the reference. The 100 µL DBS were also used to evaluate the effect of peripheral vs. central measurement of the DBS.

Next, the impact of some commonly observed ‘issues’ in the generation of DBS were evaluated: (i) pressing the DBS between the fingertips right after application of the blood, to further spread the blood (‘spot pushed’); (ii) double application of 25 µL on the same area, with a 10 s interval (‘double spotted’), (iii) holding the filter paper at an angle of approximately 45° when generating the DBS (‘angle 45°’). In addition, also DBS generated onto Ahlström 226 filter paper (not shown) and on top of a printed ‘X’ at the center of the DBS were evaluated (‘ink’). The results obtained from all these different conditions were compared against those obtained from standard 25 µL DBS. Fig. 1 shows the DBS generated under these circumstances.

Finally, the effect of several clinical parameters on the hematocrit prediction was investigated, including hemolysis, icterus and lipaemia, differing total protein concentration and differing hemoglobin glycation (HbA1c). Hereto, DBS were generated from samples with a hemolytic (n = 10, Hct range 0.314–0.510 L/L), icteric (n = 10; Hct range 0.238–0.523 L/L) and lipemic (n = 10; Hct range 0.232–0.472 L/L) (HIL) index above the cut-off value for which no interferences are expected in routine clinical analyses, respectively (H: 163–351, cut-off = 88; I: 6–29, cut-off = 5; L: 56–97, cut-off = 40). To evaluate the impact of total protein and HbA1c concentrations, DBS were generated from samples with varying total protein concentrations (n = 53, concentration range 32–99 g/L, Hct range 0.289–0.501 L/L) and varying HbA1c concentrations (n = 40, concentration range 4.48–12.9%, Hct range 0.231–0.486 L/L), respectively.

When two sample sets were compared, or when the results of the NIR measurements were compared to those obtained by the hematology
analyzer, a paired sample two-sided t-test was performed (\(\alpha = 0.05\)).
When two or more groups were compared to a reference set, repeated measures one-way ANOVA, with Dunnett post-hoc analysis (\(\alpha = 0.05\)) was used. For the analysis of the impact of varying protein and HbA1c concentrations, trend analysis using linear regression was performed.

2.6. Method comparison and application

The results obtained via NIR for the DBS validation set (\(n = 49\); singlicate analysis), measured at Day 0 and Day 5, were compared to those obtained with the hematology analyzer, being the standard method. A Bland-Altman and mountain plot were constructed, and Deming regression was performed. For the Bland-Altman plot, the maximum allowable difference was set at \(\pm 0.050\) L/L.

In addition, the method’s applicability on capillary DBS (\(n = 36\)), containing no anticoagulant, was demonstrated. Here, the Hct of the liquid capillary blood sample, determined via a Hct centrifuge, was considered as the reference value. The results obtained with both methods were compared via a Bland-Altman plot.

3. Results

3.1. Calibration model

The initial model showed two issues: first, there was an unacceptable overall negative bias; second, the predicted Hct increased with longer storage times (Supplementary Fig. 4A). Therefore, additional patient samples were included in the calibration model, and the wavenumber range 5380–4968 cm\(^{-1}\) was excluded from the calibration model. In addition, a small though significant difference was found between Hct predictions from EDTA anticoagulated DBS vs non-anticoagulated DBS. Further details on the adaptations and evaluation of the calibration model are described in the Supplementary Material Section 2.1.

3.2. Validation

The method validation amply met the pre-set acceptance criteria, with a maximum total precision of 4.5% and bias of 0.012 L/L. Also storage did not relevantly affect the Hct prediction, except for storage at 60°C. Detailed results concerning the method validation can be found in the Supplementary Material Section 2.2.

3.3. Robustness

No inter-operator variability was observed, as for 2 different operators the mean differences in predicted Hct over the 49 samples were 0.011 L/L (95% CI 0.007–0.015) and 0.002 L/L (95% CI –0.002 to 0.007) compared to the Hct measured by the standard operator.

Neither the measurement location (central vs. peripheral) nor switching from Whatman 903 filter paper to Ahlström 226 paper showed a relevant difference, with respective mean differences of \(-0.0013\) L/L (95% CI –0.015 to 0.012; \(p = 0.83\); Fig. 2A) and \(-0.004\) L/L (95% CI –0.015 to 0.006; \(p = 0.39\); Fig. 2B).

Taking a 25 µL DBS as the reference, no relevant or significant differences were found for spotted volume, except for 10 µL DBS. Although the observed difference—a decrease in predicted Hct of 0.035 L/L—was still below 0.050 L/L, it was significantly different (95% CI 0.011–0.059; \(p = 0.0019\)) (Fig. 2C). Additionally, some incorrectly or non-standard sampled DBS were generated (Fig. 2D). Only the DBS pushed after application of the blood gave a significant and relevant difference compared to the standard application of blood, with a mean difference of 0.064 L/L (95% CI 0.050–0.078 L/L; \(p < 0.0001\)).

Finally, the effect of multiple clinical parameters was evaluated. On the one hand, a high HIL-index was investigated. Only for the samples with a high hemipenic index (Fig. 3C) a significant difference was found of \(-0.035\) L/L (95% CI –0.051 to –0.019; \(p = 0.0006\)). For the icteric and hemolytic samples (Fig. 3A and B) no significant differences were found (\(p = 0.728\) and \(p = 0.59\), respectively). On the other hand, evaluation of varying total protein and HbA1c concentrations did not reveal a significant trend (Supplementary Fig. 9). Detailed results can be found in the Supplementary Material Section 2.3. Furthermore, the NIR spectrum of a dried plasma spot was found to be too different from the NIR spectrum of a DBS (Supplementary Fig. 10) to result in a hematocrit measurement (‘out of spec’ message). In contrast, the spectra of DBS with similar hematocrits but increasing HbA1c values were essentially identical (Supplementary Fig. 11).
3.4. Method comparison and application

Fig. 4 shows the results of the Bland-Altman analysis, depicting the difference between the NIR-predicted Hct and the Sysmex-measured Hct. Both for the comparison with fresh (Day 0; Fig. 4A) and 5-day old DBS (Fig. 4D) the limits of agreement (LoA) lay within the maximum allowable difference of ±0.050 L/L, with only minimal mean differences (−0.010 L/L, 95% CI −0.015 to −0.005 L/L, and 0.005 L/L, 95% CI −0.0003 to 0.0094 L/L, respectively). The trend line on Day 0 shows a negative slope, indicating that the bias increases (i.e. becomes more negative, but still within acceptance limits) with an increasing Hct. This trend was less pronounced at Day 5. The mountain plots show an even distribution of the differences around the mean differences on both days, with the differences laying between −0.044 and 0.020 L/L on Day 0 (Fig. 4B) and between −0.059 and 0.033 L/L on Day 5 (Fig. 4E). The Deming regression with the results from Day 0 showed a minimal intercept, albeit significantly different from zero (0.0245; 95% CI 0.0145–0.0344) and also 1 was not included in the 95% CI of the slope (0.916; 95% CI 0.888–0.945) (Fig. 4C). The Deming regression performed with the Hct predictions from Day 5 (Fig. 4F) no longer showed a significant deviation from 1 for the slope (0.980; 95% CI 0.945–1.016). The intercept on the other hand, while still minimal, was still significantly different from 0 (0.0144; 95% CI 0.0012–0.0277).

Finally, a Bland-Altman plot was generated from the results of the analysis of liquid (heparinized) and corresponding dried capillary blood samples (NIR-based Hct prediction from DBS), obtained via finger prick (n = 36, Fig. 5A). Here, the LoA’s lay at −0.092 and 0.005 L/L, and the mean difference was −0.043 L/L. This negative bias can be attributed to at least 2 factors. First, our evaluation (to be substantiated by larger panels) of capillary samples revealed that the Hct predicted from non-
Fig. 4. Method comparison of the NIR-predicted Hct on two validation days with the standard method (Sysmex) Hct (Day 0: A, B, C and Day 5: D, E, F). Bland-Altman plot (A and D) and mountain plot showing the distribution of the differences (B and E). Deming regression analysis (C and F).

Fig. 5. Bland-Altman comparison of the Hct of capillary DBS samples predicted via NIR and the reference method (centrifugation). In panel A, the uncorrected data are presented, in panel B, a correction of 0.030 L/L was applied to the values obtained for the Hct prediction via NIR (see Section 3.4).
anticoagulated blood is slightly underestimated compared to EDTA-
anticoagulated blood with a bias of $-0.021 \text{ L/L}$, as discussed in Sup-
plementary Material Section 2.1. The same bias may be expected here, 
since the calibration model was set up using EDTA-anticoagulated 
samples, and the samples from healthy volunteers were non-
anticoagulated. Second, an additional bias of $-0.009 \text{ L/L}$ should be 
considered, to account for the slight overestimation of the Hct via 
centrifugation-based determination versus the hematometry analyzer 
(historic validation data from the clinical laboratory from Ghent 
University Hospital). Arbitrarily correcting for these two sources of bias 
yields LoA’s at $-0.062$ and $0.035 \text{ L/L}$, with a mean difference at $-0.013 \text{ L/L}$ (Fig. 5B).

4. Discussion

A calibration model, developed and evaluated by Oostendorp et al. 
and incorporated in the NIR software, was evaluated prior to validation 
of the instrument set-up [13]. Initially, an overall unacceptable negative 
bias was seen, which exceeded the acceptance criterion of $\pm 0.050 \text{ L/L}$, 
especially in the higher Hct range (>0.50 L/L) (Supplementary Fig. 4A). 
This bias was not entirely unexpected, since this model was generated on 
another instrument several years back, and also the primary calibrator 
used for calibrating the NIR probe by the supplier was different. Hence, 
the spectra of 300 DBS (150 duplicates) were added to the model. Sec-
ondly, a time-dependent bias was observed, both in the evaluation of 
the initial and the updated model (Supplementary Fig. 4A and B). Analysis 
of some NIR spectra revealed a wavenumber range (5380–4968 cm$^{-1}$) 
with a higher variation in reflectance over time compared to the other 
ranges. This range reflects a typical range in the NIR spectrum for H$_2$O/ 
OH overtones [19], and hence a differential presence of water in the 
samples due to their different storage time may explain this variation. In 
the recent report by van de Velde et al. a partially overlapping wavenum-
ber range (5800–5000 cm$^{-1}$) was also excluded from the calibration 
model, for the same reason [14]. After exclusion of this wavenumber 
range, the Hct predictions showed less variation over time, yielding 
the final calibration model.

Next, the number of samples added to the calibration model was 
evaluated (Supplemental Tables 2 and 3). Except for the model without 
additional samples, all models still yielded validation results within the 
acceptance criteria, and, hence, less samples (30 duplicate DBS) may 
suffice to update the calibration model and reduce the bias, if needed. In 
any case, upon implementation of the instrument set-up it should be 
evaluated if the method performance is fit-for-purpose.

Furthermore, when using spectroscopic methods, re-evaluation of 
the method performance on a regular basis can be necessary, e.g. after 
movement of the system to another place, after maintenance/repair, or 
when transferring the calibration model to another NIR spectrometer. 
This can easily be done by adding the spectra of a small set of additional 
patient samples spread over the Hct range.

Finally, prior to starting the method validation, a preliminary eval-
uation of the effect of the used anticoagulant was performed, which 
revealed a slight, though significant, difference in predicted Hct be-
tween non- and EDTA-anticoagulated DBS, the latter being on average 
0.021 L/L higher (Supplementary Material Sections 1.2 and 2.1). 
However, more samples are needed to substantiate this difference. The 
same observation (i.e. lower values obtained from non-anticoagulated 
blood) was made in the preliminary evaluation by Lange et al., who 
also suggested to further investigate the influence of EDTA on the Hct 
prediction [20].

The method validation, which was entirely performed using patient 
samples, demonstrated that accurate and precise (maximal bias was 
0.012 L/L, maximal total CV was 4.5%) results can be obtained with a 
currently commercially available NIR set-up. The performance of the 
method is comparable to that of other published methods for the non-
destructive Hct prediction from DBS [10,14].

Although the Deming regression analysis showed that there were 
unsystematic and proportionally different increases between the evaluated NIR 
method and the reference method, these differences were small and no 
correction of the predicted Hct or adaptation of the calibration model is 
needed. This is also reflected in the Bland-Altman plots, comparing the 
results from the validation sample set on Day 0 and Day 5 with the 
standard method which yielded LoA’s smaller than the pre-set maximum 
allowable differences of $\pm 0.050 \text{ L/L}$. These limits were chosen based on 
the purpose of the method: to give an estimation of the Hct, to then (i) 
allow correction of an analytical result, (ii) evaluate whether the Hct is 
in a predefined range, or (iii) convert DBS-based results to plasma 
or serum values.

In the second part of the study, we demonstrated the pre-analytical 
robustness of the method. First, sample storage did not relevantly 
affect the Hct prediction of the DBS, except for DBS stored at 60°C. 
However, for TDM purposes, it is unlikely that samples will be exposed 
to these extreme conditions. As samples destined for TDM are usually 
not stored for a long period of time prior to analysis, stability upon 
storage was limited to 1 month. Importantly, also storage without a 
desiccant still yielded reliable results, which is relevant in case of home-
sampling, where the addition of a desiccant may be forgotten. Also 
shorter drying times did not markedly influence the Hct prediction, 
which would allow to analyze samples on the day of the sample 
collection, as may be the case in a hospital context. However, the drying 
time is ideally longer than 2 h, otherwise an underestimation may be 
present for low-Hct DBS.

In addition, the method is very robust towards several aspects 
including measurement location and filter paper. Also, spotted volumes 
of 17 µL and more yielded reliable results. Only a volume of 10 µL 
resulted in a slight underestimation of the Hct, which may be attributed 
to the filter paper being less saturated, and/or to a suboptimal posi-
tioning of the DBS under the NIR probe, due to its small area. For 
finger prick samples, it is our experience that a typical DBS will exceed a 
volume of 10 µL, but one could opt to use pre-printed circles defining the 
minimal area that a DBS should cover. For devices like the Hemaxis DB 
10, which volumetrically generates 10 µL DBS on classical DBS cards 
[21] this underestimation might be relevant, although the mean bias 
was only 0.035 L/L.

The analysis of samples with a high HIL-index showed that only 
lipemia had a significant effect on the Hct predictions. The mean dif-
ference was 0.035 L/L, which was considered acceptable.

Since hemoglobin is a protein, we evaluated whether other proteins 
present in plasma (e.g. albumin and globulin) may affect the recorded 
spectrum and, consequently, the Hct prediction. However, no relevant 
trend was observed across a protein concentration range of 32–90 g/L. 
This was further supported by the observation that the spectrum ob-
tained from a plasma sample is only similar to the spectrum of a whole 
blood sample to a certain extent (Supplemental Fig. 10).

Furthermore, the effect of hemoglobin glycation on the Hct predic-
tion was also investigated, as in literature it has already been reported 
that glycation may have an impact on the NIR spectrum obtained from 
nail clippings (e.g. keratin vs glycated keratin in nails) [22]. In the range 
of 4.48–12.9% HbA1c no relevant effects were seen. Moreover, the 
spectra of samples with similar hematocrit but increasing HbA1c values 
were almost identical, which further supports this result (Supplemental 
Fig. 11).

Finally, different unconventional applications of blood onto the filter 
paper were also evaluated. Again, the method proved robust against 
these elements. Of note, and importantly, the NIR approach did yield a 
different (i.e. lower) result for DBS which had been pressed after 
application of the blood. Such tampering is sometimes seen when 
insufficient instructions or training is given to the person collecting the 
DBS samples, who are instructed to “fill the pre-printed circle” and do so 
by increasing the area that is covered by a drop of blood. Evidently, a 
differential spreading of the blood, which is the case when pressure is 
exerted to the filter paper, will affect both the amount of analyte per area 
and the Hct prediction, since the volume of blood spread over a certain
area changes (in this case decreases). Knowledge of the Hct may thus allow correction for this tampering.

The potential for real-life use of the technology, was further revealed by demonstrating its applicability on capillary samples. The original Bland-Altman plot of the capillary DBS samples revealed a mean bias of −0.043 L/L compared to the reference method. Following correction for two sources of bias, this bias was reduced to −0.013 L/L. In an attempt to completely remove the bias, the model was re-evaluated to search for differences in the NIR spectrum between non- and EDTA-anticoagulated DBS, and exclude these from the calibration model. However, no important differences could be identified. Therefore, as from a practical point-of-view it is virtually impossible to set-up a calibration model using non-anticoagulated samples, we propose—and implemented here—an arbitrary correction factor for the Hct prediction in non-anticoagulated DBS. To confirm this correction factor ( provisionally set at 0.030 L/L), an even more extensive set of capillary liquid blood samples and corresponding DBS should be collected, covering a Hct range as wide as possible. Besides the observation of a bias in capillary samples, the span between the upper and lower LoA was wider compared to that found in the Bland-Altman plots of the validation sample sets. This increase could be expected, as the validation was performed with DBS generated via pipetting a fixed volume onto the filter paper under well controlled circumstances, while more variation can be expected upon collecting capillary DBS. Nonetheless, eventually, 34/36 Hct predictions from capillary DBS differed less than 0.050 L/L from the reference Hct value, demonstrating the potential of the technology for Hct prediction of DBS generated from capillary, non-anticoagulated blood. In future, more samples, preferably covering a wider Hct range, may be used to further confirm the application on capillary DBS.

5. Conclusion

After updating the initially incorporated calibration model, a commercially available NIR set-up was successfully validated, yielding acceptable accuracy and precision results for NIR-based Hct prediction of DBS. Stability experiments showed that DBS can be stored up till 1 month at RT or lower temperatures without a relevant effect on the Hct value, demonstrating its application potential in real-life settings.

Acknowledgements

The authors wish to acknowledge Prof. Veronique Stove, Evelyne Jacobs, Nick Veroogtstraete, and the team of the clinical laboratory at Ghent University Hospital for their help with the sample collection and hematocrit measurements. The authors want to thank all volunteers who participated in the study.

Competing interests

Dr. Christoph Lühr is an employee of BÜCHI Labortechnik GmbH (Essen, Germany). The research presented here was independently conducted at Ghent University, without any steering by BÜCHI Labortechnik or Dr. Lühr. As Dr. Lühr did provide essential scientific input related to data analysis and troubleshooting, the lead author (C. Stove) invited him to be co-author on this paper, in line with proper scientific conduct. None of the other authors has any competing interest.

Funding

Liesl Heughebaert would like to thank the Special Research Fund (BOF) for granting her a PhD fellowship (01D05220).

Ethical approval

Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors’ Institutional Review Board (EC2018/0519).

Informed consent

Informed consent was obtained from all healthy volunteers included in this study. For the use of left-over samples the Ethics Committee granted an exemption for the informed consent.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cca.2021.10.002.

References

[1] R. Guthrie, A. Suni, A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants, Pediatrics 32 (1963) 328–334.
[2] C.P. Stove, A.S. Ingels, P.M. De Kezel, W.E. Lambert, Dried blood spots in toxicology: from the cradle to the grave? Crit. Rev. Toxicol. 42 (3) (2012) 230–243.
[3] P.M. De Kezel, N. Sadones, S. Capiau, W.E. Lambert, C.P. Stove, Hemat-critical issues in quantitative analysis of dried blood spots: challenges and solutions, Bioanalysis 5 (16) (2013) 2023–2041.
[4] P. Abu-Rabie, P. Denniff, N. Spooner, B.Z. Chowdhry, F.S. Pullen, Investigation of different approaches to incorporating internal standard in DBS quantitative bioanalytical workflows and their effect on nullifying hematocrit-based assay bias, Anal. Chem. 87 (9) (2015) 4996–5003.
[5] E.M. Hall, S.R. Flores, V.R. De Jesus, Influence of Hematocrit and Total-Spot Volume on Performance Characteristics of Dried Blood Spots for Newborn Screening, Int. J. Neonatal. Screen. 1 (2) (2015) 69–78.
[6] A.J. Lawson, L. Bernstone, S.K. Hall, Newborn screening blood spot analysis in the UK: influence of spot size, punch location and haematocrit, J. Med. Screen. 23 (2) (2016) 7–16.
[7] S. Velghe, L. Delahaye, C.P. Stove, Is the hematocrit still an issue in quantitative dried blood spot analysis? J. Pharm. Biomed. Anal. 163 (2019) 188–196.
[8] S. Capiau, I.S. Wilk, M.C.G. Alders, C.P. Stove, A. Novel, Nondestructive, Dried Blood Spot-Based Hematocrit Prediction Method Using Noncontact Diffuse Reflectance Spectroscopy, Anal. Chem. 88 (12) (2016) 6538–6546.
[9] S. Capiau, C. Stove, Hematocrit prediction in volumetric absorptive microsamples, J. Pharm. Biomed. Anal. 190 (2020) 113491, https://doi.org/10.1016/j.jbpa.2020.113491.
[10] S. Capiau, I.S. Wilk, P.M.M. De Kezel, M.C.G. Alders, C.P. Stove, Correction for the Hematocrit Bias in Dried Blood Spot Analysis Using a Nondestructive, Single-Wavelength Reflectance-Based Hematocrit Prediction Method, Anal. Chem. 90 (3) (2018) 1795–1804.
[11] P.M.M. De Kezel, S. Capiau, V.V. Stove, W.E. Lambert, C.P. Stove, Potassium-based algorithm allows correction for the hematocrit bias in quantitative analysis of caffeine and its major metabolite in dried blood spots, Anal. Bioanal. Chem. 406 (26) (2014) 6749–6755.
[12] K. Bloem, T. Schaap, R. Booshuizen, E.L. Kneckevis, G.J. Volbink, A. Vries, T. Rispens, Capillary blood microsampling to determine serum biochemical concentrations: Mitra(R) microsample vs dried blood spot, Bioanalysis 10 (11) (2018) 815–823.
[13] M. Oostendorp, M. El Amrani, E.C. Diemel, D. Hekman, E.M. van Maarseveen, Measurement of Hematocrit in Dried Blood Spots Using Near-Infrared Spectroscopy: Robust, Fast, and Nondestructive, Clin. Chem. 62 (11) (2016) 1534–1536.
[14] D. van de Velde, J.L. van der Graaf, M. Boussaidi, R. Huisman, D.A. Hesselink, J. Pharm. Biomed. Anal. 190 (2020) 113491, https://doi.org/10.1016/j.jpba.2020.113491.
[15] M. Lugjubhul, Y. Fischer, S. Gaugler, Fully Automated Optical Hematocrit Measurement From Dried Blood Spots, J. Anal. Toxicol. (2020).
[16] European Medicines Agency, Guideline on bioanalytical method validation, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin e/2011/08/WC500199686.pdf (Accessed February 22 2021).
[17] U.S. Department of Health and Human Services Food and Drug Administration, Bioanalytical Method Validation. Guidance for Industry, 2018. https://www.fda.gov/downloads/drugs/guidances/ucm5003.

245
[18] S. Capiau, H. Veenhof, R.A. Koster, Y. Bergqvist, M. Boettcher, O. Halmingh, B. G. Keervil, B.C.P. Koch, R. Linden, C. Pistos, L.M. Stolk, D.J. Tonw, C.P. Stove, J. C. Alffenaar, Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring, Ther. Drug Monit. 41 (4) (2019) 409–430.

[19] Z. Xiaobo, Z. Jiewen, M.J.W. Povey, M. Holmes, M. Hanpin, Variables selection methods in near-infrared spectroscopy, Anal. Chim. Acta 667 (1-2) (2010) 14–32.

[20] T. Lange, A. Thomas, K. Walpurgis, M. Thevis, Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS, Anal. Bioanal. Chem. 412 (15) (2020) 3765–3777.

[21] HemaXis DB 10. https://hemaxis.com/products/hemaxis-db10/ (Accessed May 14 2020).

[22] T. Monteyne, R. Coopman, A.S. Kishabongo, J. Himpe, B. Lapauw, S. Shadid, E. H. Van Aken, D. Berrens, M.M. Speckaert, T. De Beer, J.R. Delanghe, Analysis of protein glycation in human fingernail clippings with near-infrared (NIR) spectroscopy as an alternative technique for the diagnosis of diabetes mellitus, Clin. Chem. Lab. Med. 56 (9) (2018) 1551–1558.